Evidence map›Paper›PMID 38686946›Full record

ArticleInternational journal of immunopathology and pharmacology

Clinical role of NDRG2-based methylation status on survival pattern of glioblastoma.

Menha Swellam, Mohamed K Khalifa, Amira M Nageeb, Lobna Ezz El-Arab, Manal El-Mahdy, Khaled El-Bahy, Magda Sayed Mahmoud

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Menha SwellamBiochemistry Department, Biotechnology Research Institute, National Research Centre, Dokki, Giza, Egypt.ORCID 0000-0002-7104-7194
Mohamed K KhalifaCSO at Omnicsense, Giza, Egypt.
Amira M NageebBiochemistry Department, Biotechnology Research Institute, National Research Centre, Dokki, Giza, Egypt.
Lobna Ezz El-ArabClinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Manal El-MahdyPathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Khaled El-BahyDepartment of Neurosurgery, Faculty of Medicine, Ain Sham University, Cairo, Egypt.
Magda Sayed MahmoudBiochemistry Department, Biotechnology Research Institute, National Research Centre, Dokki, Giza, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesGliobalstoma is the most common primary brain tumor in adults with an extensive genetic and transcriptional heterogeneity, still identification of the role of DNA methylation, as one of epigenetic alterations, is emerged. Authors aimed to study the clinical role of N-myc downstream-regulated gene 2 (NDRG2) -based methylation among GBM patients versus benign neurological diseases (BND), investigate its prognostic role and its relation with survival outcomes.

methodsA total of 78 FFPE specimens were recruited as follows: GBM (

resultsMean methylation NDRG2 level was significantly increased in GBM patients as compared to BND and its sensitivity and specificity were 96.55% and 95%, respectively with area under curve (AUC) equals 0.973. Among the clinical characteristic factors, mean methylation level reported significant difference with ECOG and tumor site. Survival out comes revealed that NDRG2 methylation increased with worse PFS and OS at significant level (long rank test

conclusionCurrent findings highlight the importance of studying DNA methylation of NDRG2 as a key factor to understand the role of epigenetic alterations in GBM.

Indexed as

Brain NeoplasmsDNA MethylationGlioblastomaTumor Suppressor ProteinsAdultAgedBiomarkers, TumorEpigenesis, GeneticFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisBiomarkers, TumorNDRG2 protein, humanTumor Suppressor ProteinsDNA methylationGlioblastomaNDRG2Survival pattern

Identifiers

PMID38686946
PMCPMC11062227

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.